Andrey Zarur, GreenLight Biosciences CEO

Q&A: De­ter­mined to not re­peat mis­takes from the last pan­dem­ic, An­drey Zarur talks about lat­est deal with Serum In­sti­tute

The Mass­a­chu­setts biotech Green­Light made waves Mon­day with the an­nounce­ment of its li­cens­ing deal with the Serum In­sti­tute of In­dia. Three of its mR­NA prod­ucts, start­ing with its shin­gles vac­cine, will be pro­duced by Serum in a deal that pig­gy­backs off of its $10 mil­lion in­vest­ment from No­vem­ber.

Green­Light is rid­ing high off of its re­verse merg­er that net­ted it­self a $1.5 bil­lion val­u­a­tion, af­ter it merged with the SPAC En­vi­ron­men­tal Im­pact Ac­qui­si­tion Corp. It’s still work­ing on ex­per­i­men­tal vac­cines and ther­a­pies us­ing mR­NA tech­nol­o­gy for the sea­son­al flu and sick­le cell dis­ease, a long way from where it orig­i­nal­ly got its start: shak­ing up the pes­ti­cides mar­ket for agri­cul­ture.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.